124 related articles for article (PubMed ID: 37914142)
1. SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection.
Farooqi AS; Yoder AK; Lin HY; Pasalic D; Erasmus J; Betancourt S; Wernz C; Mitra D; Zarzour MA; Somaiah N; Conley A; Ratan R; Livingston A; Araujo DM; Roland C; Scally C; Keung E; Gandhi SN; Ashleigh Guadagnolo B; Nguyen QN; Bishop AJ
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(4):971-978. PubMed ID: 37914142
[TBL] [Abstract][Full Text] [Related]
2. Improved local control following dose-escalated stereotactic ablative radiation therapy (SABR) for metastatic sarcomas: An international multi-institutional experience.
Singh R; Konrad A; Roubil JG; Jenkins J; Davis J; Austin Vargo J; Gogineni E; Sharma S
Radiother Oncol; 2024 Jan; 190():110020. PubMed ID: 38007042
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and the Role of Primary Histology Following LINAC-based Stereotactic Radiation for Sarcoma Brain Metastases.
Sim AJ; Ahmed KA; Keller A; Figura NB; Oliver DE; Sarangkasiri S; Robinson TJ; Johnstone PAS; Yu HM; Naghavi AO
Am J Clin Oncol; 2020 May; 43(5):356-361. PubMed ID: 32217854
[TBL] [Abstract][Full Text] [Related]
5. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.
Brooks ED; Sun B; Feng L; Verma V; Zhao L; Gomez DR; Liao Z; Jeter M; O'Reilly M; Welsh JW; Nguyen QN; Erasmus JJ; Eapen G; Ahrar K; Antonoff MB; Hahn SM; Heymach JV; Rice DC; Chang JY
JAMA Netw Open; 2018 Aug; 1(4):e181390. PubMed ID: 30646121
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma.
McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.
Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U
Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic ablative radiation therapy for pulmonary metastases: Improving overall survival and identifying subgroups at high risk of local failure.
Pasalic D; Lu Y; Betancourt-Cuellar SL; Taku N; Mesko SM; Bagley AF; Chance WW; Allen PK; Tang C; Antonoff MB; Balter PA; Mehran RJ; Welsh JW; Liao Z; Gomez D; Erasmus JJ; Nguyen QN
Radiother Oncol; 2020 Apr; 145():178-185. PubMed ID: 32044530
[TBL] [Abstract][Full Text] [Related]
9. Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease.
He K; Hong DS; Tang C; Sezen D; Cox L; Maleki A; Bertolet G; Nguyen QN; Comeaux NI; Schuda L; Chen D; Welsh JW
Radiother Oncol; 2023 Jun; 183():109618. PubMed ID: 36921766
[TBL] [Abstract][Full Text] [Related]
10. Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.
Deek MP; Taparra K; Phillips R; Velho PI; Gao RW; Deville C; Song DY; Greco S; Carducci M; Eisenberger M; DeWeese TL; Denmeade S; Pienta K; Paller CJ; Antonarakis ES; Olivier KR; Park SS; Tran PT; Stish BJ
Eur Urol Oncol; 2021 Jun; 4(3):447-455. PubMed ID: 32536574
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival.
Billingsley KG; Burt ME; Jara E; Ginsberg RJ; Woodruff JM; Leung DH; Brennan MF
Ann Surg; 1999 May; 229(5):602-10; discussion 610-2. PubMed ID: 10235518
[TBL] [Abstract][Full Text] [Related]
12. Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial.
Baker S; Jiang W; Mou B; Lund CR; Liu M; Bergman AM; Schellenberg D; Alexander AS; Carolan H; Atrchian S; Chng N; Matthews Q; Arbour G; Benny A; Tyldesley S; Olson RA
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):617-626. PubMed ID: 35667528
[TBL] [Abstract][Full Text] [Related]
13. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Iyengar P; Wardak Z; Gerber DE; Tumati V; Ahn C; Hughes RS; Dowell JE; Cheedella N; Nedzi L; Westover KD; Pulipparacharuvil S; Choy H; Timmerman RD
JAMA Oncol; 2018 Jan; 4(1):e173501. PubMed ID: 28973074
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity.
Chance WW; Nguyen QN; Mehran R; Welsh JW; Gomez DR; Balter P; Komaki R; Liao Z; Chang JY
Pract Radiat Oncol; 2017; 7(3):e195-e203. PubMed ID: 27743801
[TBL] [Abstract][Full Text] [Related]
15. Can Multistate Modeling of Local Recurrence, Distant Metastasis, and Death Improve the Prediction of Outcome in Patients With Soft Tissue Sarcomas?
Posch F; Leitner L; Bergovec M; Bezan A; Stotz M; Gerger A; Pichler M; Stöger H; Liegl-Atzwanger B; Leithner A; Szkandera J
Clin Orthop Relat Res; 2017 May; 475(5):1427-1435. PubMed ID: 28083752
[TBL] [Abstract][Full Text] [Related]
16. Can dosimetry affect local control and survival in patients with early-stage lung cancer treated with Stereotactic Ablative Radiotherapy (SABR)? An analysis of the UK's largest cohort of lung SABR patients.
Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
Acta Oncol; 2021 Apr; 60(4):505-512. PubMed ID: 33491521
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes for Stereotactic Ablative Radiotherapy in Oligometastatic and Oligoprogressive Gynecological Malignancies.
Mesko S; Sandler K; Cohen J; Konecny G; Steinberg M; Kamrava M
Int J Gynecol Cancer; 2017 Feb; 27(2):403-408. PubMed ID: 27870704
[TBL] [Abstract][Full Text] [Related]
18. How Are Indeterminate Pulmonary Nodules at Diagnosis Associated with Survival in Patients with High-Grade Osteosarcoma?
Tsoi KM; Lowe M; Tsuda Y; Lex JR; Fujiwara T; Almeer G; Gregory J; Stevenson J; Evans SE; Botchu R; Jeys LM
Clin Orthop Relat Res; 2021 Feb; 479(2):298-308. PubMed ID: 32956141
[TBL] [Abstract][Full Text] [Related]
19. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
